Search results
Results from the WOW.Com Content Network
Astellas Pharma office in Canada. Astellas Pharma Inc. (アステラス製薬株式会社, Asuterasu Seiyaku Kabushiki-gaisha) is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社, Yamanouchi Seiyaku Kabushiki-gaisha) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 ...
The top 5 best selling pharmaceuticals 2015–2019. Sales in billion USD. [1] Rank Drug ... Astellas Pharma US: Overactive bladder: Feb-2000: 2018-Nov 68: Dexilant:
(Reuters) - Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues ...
OSI Pharmaceuticals, Inc. was an American pharmaceutical company formerly based in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. On Sunday, May 16, 2010 OSI agreed to be acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion. [4] The deal was closed on June 9, 2010.
Astellas Pharma, Japan's No. 2 drugmaker, has wanted to get a footprint in the U.S. market. And this means making an acquisition. So, Astellas has spent 13 months trying to purchase OSI ...
The U.S. government, late last month, selected the first 10 drugs, including the top-selling blood thinner Eliquis from Bristol Myers Squibb and Pfizer, which will face price negotiations as part ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Ipragliflozin (INN, [2]: 69 trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014, [3] and in Russia on May 22, 2019. [4] Ipragliflozin is a Sodium/glucose cotransporter 2 (SGLT2) inhibitor . [5]